Well that is disappointing
“The study did not meet its primary efficacy endpoint of MACE reduction at 90 days. As a result, there are no plans for a near-term regulatory filing. There were no major safety or tolerability concerns with CSL112.”
the leading health company stumbles again.
Well that is disappointing “The study did not meet its primary...
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$285.10 |
Change
-6.060(2.08%) |
Mkt cap ! $138.0B | |||
| Open | High | Low | Value | Volume |
| $289.85 | $291.99 | $285.10 | $215.2M | 748.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2976 | $285.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $286.53 | 75 | 1 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| CSL (ASX) Chart |